CCS1477 is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer. CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.

Status current

Associated Fund UK Innovation & Science Seed Fund

Sector Medical / Biotechnology


“Interactions with Midven have always been open and straightforward. Investments have always been clearly structured and compatible with others, including high net worths, Institutional and corporate investors.”

Will West, Cellcentric


Associated Team Members

Relevant News

CellCentric raises $26 million to take first-in-class p300/CBP inhibitor into the clinic

May 15th 2018 CellCentric has raised $26 million in private financing to fund clinical testing…

read more

CellCentric’s first-in-class p300/CBP inhibitor drug CCS1477; capsule production complete ready for the clinic

Production of CCS1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical trials…

read more

CellCentric wins Innovate UK award to expand use of p300/CBP inhibitors in cancer

CellCentric is developing first in class drug compounds against a key regulator of cancer. P300/CBP…

read more

CellCentric Gains £4.3m To Take Prostate Cancer Programme Through To Clinical Candidates

New investment coupled with a major award from the UK’s innovation agency, the Technology Strategy…

read more

More Companies in Medical / Biotechnology